Absci Corporation announced positive interim Phase 1 results for ABS-201, an investigational antibody targeting the prolactin receptor to treat androgenetic alopecia (pattern hair loss). The study showed ABS-201 was well tolerated with no serious adverse events and an estimated half-life of at least 65 days, supporting dosing every two to three injections over six months. The trial has progressed to multiple ascending doses in patients with hair loss, with interim proof-of-concept data expected in late 2026 and full data in early 2027. This novel treatment could offer a new option beyond current limited therapies like minoxidil and finasteride.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
